Real-World Effectiveness and Safety of Single Inhaler Triple Therapy with Beclometasone/ Formoterol/ Glycopyrronium in Moderate to Severe Asthma: TriMaximize Study
Extrafine, single-inhaler BDP/FF/G therapy was effective and safe in a routine clinical practice setting in a multi-national cohort of patients with moderate to severe asthma.
Authors
- Marek Lommatzsch (ORCID: https://orcid.org/0000-0002-9305-9348)
- Maciej Kupczyk (ORCID: https://orcid.org/0000-0003-0800-7867)
- Valentina Bogoevska
- Christian Geßner
- Wolfgang Pohl
- Fulvio Braido
- Alessio Piraino
- Richard Russell
- Timm Greulich
- Arnaud Bourdin
- Frederik Trinkmann
- Ulrica Scaffidi-Argentina
- Vicente Plaza
- Charlotte Suppli Ulrik
Institutions
- King's College London (GB)
- Heidelberg University (DE)
- Hospital de Sant Pau (ES)
- Hvidovre Hospital (DK)
- University Hospital Heidelberg (DE)
- Klinik Hietzing (AT)
- Chiesi (Germany) (DE)
- Medical University of Lodz (PL)
- Chiesi Foundation (IT)
- German Center for Lung Research (DE)
- Pulmonary Associates (US)
- Ospedale Policlinico San Martino (IT)
- Hôpital Arnaud de Villeneuve (FR)
- University Medical Centre Mannheim (DE)
- Chiesi (Italy) (IT)
- University of Rostock (DE)
- Leipzig University (DE)
Publication Details
- Journal
- Journal of Asthma and Allergy
- Published
- 2026-02-01
- DOI
- https://doi.org/10.2147/jaa.s582286
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Teva Pharmaceutical Industries
- Regeneron Pharmaceuticals
- Celltrion
- Menarini Group
- Cilag